Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of dekaparin to replace animal-sourced heparin

Award Number: R44HL139187
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Development of dekaparin to replace animal-sourced heparin - The goal of this proposal is to develop dekaparin, a synthetic glycan, to replace animal-derived low molecular weight heparins (LMWHs). LMWHs are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to 12-20 saccharide units. The efficient preparation of a synthetic LMWH could improve the safety, availability and efficacy. However, the production of homogeneous LMWHs has not been possible due to difficulties in the synthesis. Glycan Therapeutics proposes to assess an innovative chemoenzymatic approach that would provide an unprecedented efficiency in the preparation of heparin. Our product will be animal-free, structurally homogenous, safe for renal-impaired patients, and have the ability of its anticoagulant activity to be neutralized by protamine. In the presently proposed SBIR Phase IIB grant application, we will conduct the synthesis of dekaparin under the GMP conditions and complete the formulation, which will clear the IND requirements by FDA. Glycan Therapeutics will also develop a 505(b)(2) regulatory strategy to shorten the regulatory pathway. The completion of this project will modernize this century-old drug with improved safety and anticoagulant properties.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $991,212 )
2025	2025	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Blood Diseases and Resources Research	000	5	9/17/2025	NON-COMPETING CONTINUATION	$991,212
														Subtotal = $991,212

Issue Date FY: 2024 ( Subtotal = $746,918 )
2024	2024	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Blood Diseases and Resources Research	001	4	9/17/2024	COMPETING CONTINUATION	$747,280
2024	2020	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Blood Diseases and Resources Research	000	3	11/21/2023	NON-COMPETING CONTINUATION	-$362
														Subtotal = $746,918

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	GLYCAN THERAPEUTICS LLC	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Blood Diseases and Resources Research	000	3	10/26/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $1,248,861 )
2020	2020	GLYCAN THERAPEUTICS LLC	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Blood Diseases and Resources Research	000	3	6/19/2020	NON-COMPETING CONTINUATION	$1,248,861
														Subtotal = $1,248,861

Issue Date FY: 2019 ( Subtotal = $1,244,412 )
2019	2019	GLYCAN THERAPEUTICS LLC	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Cardiovascular Diseases Research	000	2	7/3/2019	COMPETING CONTINUATION	$1,244,412
														Subtotal = $1,244,412

Grand Total All Awards = $4,231,403

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of dekaparin to replace animal-sourced heparin

Award Number: R44HL139187

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer